In a series of experiments using purified multiple myeloma cells, multiple myeloma cell lines, full bone marrow mononuclear cell suspensions derived from multiple myeloma patients and peripheral blood mononuclear cells isolated from lenalidomide-treated patients, we show that the combination of lenalidomide and daratumumab significantly increases the lysis of multiple myeloma cells as compared to either of the single agents

Posted on by Courtney Roberts

In a series of experiments using purified multiple myeloma cells, multiple myeloma cell lines, full bone marrow mononuclear cell suspensions derived from multiple myeloma patients and peripheral blood mononuclear cells isolated from lenalidomide-treated patients, we show that the combination of lenalidomide and daratumumab significantly increases the lysis of multiple myeloma Continue Reading